関節リウマチ治療薬の市場規模、シェア、成長分析、分子別、販売チャネル別、投与経路別、地域別 - 産業予測、2025-2032年

関節リウマチ治療薬の世界市場規模は2023年に258億米ドルと評価され、2024年の273億5,000万米ドルから2032年には435億9,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは6.0％で成長する見通しです。

世界の関節リウマチ治療薬市場は、関節炎や関節合併症の罹患率の上昇に牽引され、大きな成長を遂げています。関節リウマチの有病率の増加、関連薬の需要、特許切れ、バイオシミラーの出現などの要因が、この拡大に極めて重要です。人口の高齢化に加え、従来の疾患修飾性抗リウマチ薬（DMARDs）の使用率が高まっていることや、国民の意識を高め革新的な治療研究を奨励する政府の積極的な取り組みが、市場のダイナミクスをさらに強化しています。著名な業界企業との提携や医療改革の活発化により、これらの治療法の研究や採用が促進されています。相乗効果をもたらす併用療法の動向もまた、多面的な治療アプローチから大きな恩恵を受けることができる患者への対応として、支持を集めています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 技術分析

関節リウマチ治療薬市場規模：分子別

• 市場概要
• 医薬品
  • 非ステロイド性抗炎症薬
  • 鎮痛剤
  • 抗リウマチ薬
  • グルココルチコイド
• バイオ医薬品
  • 生物学的製剤
    • TNF-αアンタゴニスト
    • T細胞阻害剤
    • CD20抗体
    • JAK阻害剤
    • 抗IL6生物学的製剤
  • バイオシミラー
    • CD20抗原
    • TNF-αアンタゴニスト

関節リウマチ治療薬市場規模：販売チャネル別

• 市場概要
• 処方箋
• 市販薬（OTC）

関節リウマチ治療薬市場規模：投与経路別

• 市場概要
• 経口
• 非経口

関節リウマチ治療薬市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• AbbVie Inc.（USA）
• Pfizer Inc.（USA）
• Amgen Inc.（USA）
• Eli Lilly and Company（USA）
• Bristol-Myers Squibb Company（USA）
• Johnson & Johnson（USA）
• Novartis AG（Switzerland）
• F. Hoffmann-La Roche Ltd（Switzerland）
• UCB S.A.（Belgium）
• Takeda Pharmaceutical Company Limited（Japan）
• Astellas Pharma Inc.（Japan）
• Eisai Co., Ltd.（Japan）
• Chugai Pharmaceutical Co., Ltd.（Japan）
• Kyowa Kirin Co., Ltd.（Japan）
• Sun Pharmaceutical Industries Ltd.（India）
• Lupin Limited（India）
• Zydus Lifesciences Limited（India）
• Cipla Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）

結論と提言

Global Rheumatoid Arthritis Drugs Market size was valued at USD 25.8 billion in 2023 and is poised to grow from USD 27.35 billion in 2024 to USD 43.59 billion by 2032, growing at a CAGR of 6.0% during the forecast period (2025-2032).

The global rheumatoid arthritis drugs market is experiencing significant growth, driven by the rising incidence of arthritis and joint complications. Factors such as the increasing prevalence of rheumatoid arthritis, the demand for related medications, patent expirations, and the emergence of biosimilars are pivotal in this expansion. The ageing population, combined with a greater utilization of conventional Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and proactive government initiatives to enhance public awareness and encourage innovative treatment research, further bolster market dynamics. Collaborations with prominent industry players and increased healthcare reforms are fostering research and adoption of these therapies. The trend towards combination therapies, offering synergistic benefits, is also gaining traction, catering to patients who can significantly benefit from a multifaceted treatment approach.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Rheumatoid Arthritis Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Rheumatoid Arthritis Drugs Market Segments Analysis

Global Rheumatoid Arthritis Drugs Market is segmented by Molecule, Sales Channel, Route of Administration and region. Based on Molecule, the market is segmented into Pharmaceuticals and Biopharmaceuticals. Based on Sales Channel, the market is segmented into Prescription and Over-the-Counter (OTC). Based on Route of Administration, the market is segmented into Oral and Parenteral. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Rheumatoid Arthritis Drugs Market

The growing prevalence of rheumatoid arthritis worldwide serves as a significant driver for the expansion of the global rheumatoid arthritis drugs market. With an aging population and changing dietary habits contributing to the rise in cases of this debilitating condition, there is an increasing demand for effective treatment solutions. This heightened need for innovative and efficient therapies underscores the urgency for advancements in this sector, thereby fostering market growth. As efforts to address the challenges of rheumatoid arthritis continue to evolve, the global market for related pharmaceuticals is poised for significant development in response to these pressing healthcare needs.

Restraints in the Global Rheumatoid Arthritis Drugs Market

Concerns regarding the safety of long-term use of certain rheumatoid arthritis medications, particularly biologics and JAK inhibitors, present a significant challenge to the growth of the market. Both patients and healthcare professionals often hesitate to utilize these therapies due to potential adverse effects, including an increased risk of infections, cardiovascular issues, and cancer. This reluctance impacts the rate at which these treatments are adopted and integrated into clinical practice, ultimately slowing their acceptance and market penetration. As a result, these safety apprehensions create a notable restraint on the overall expansion of the global rheumatoid arthritis drugs market.

Market Trends of the Global Rheumatoid Arthritis Drugs Market

The global rheumatoid arthritis drugs market is experiencing a significant trend towards the adoption of biologic therapies, which encompass advanced treatments such as monoclonal antibodies and Janus kinase (JAK) inhibitors. These innovative drugs are gaining traction due to their targeted mechanisms of action, offering enhanced efficacy and a favorable safety profile compared to traditional therapies. As healthcare providers and patients increasingly recognize the benefits of biologics in managing moderate to severe rheumatoid arthritis, their market penetration continues to rise. This shift towards biologic treatments is poised to reshape the landscape of rheumatoid arthritis therapeutics, driving growth and innovation in the industry.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Analysis

Global Rheumatoid Arthritis Drugs Market Size by Molecule & CAGR (2025-2032)

• Market Overview
• Pharmaceuticals
  • NSAIDs
  • Analgesics
  • DMARDs
  • Glucocorticoids
• Biopharmaceuticals
  • Biologics
    • TNF-a antagonists
    • T-cell inhibitors
    • CD20 antigen
    • JAK inhibitors
    • anti-IL6 biologics
  • Biosimilars
    • CD20 antigen
    • TNF-a antagonists

Global Rheumatoid Arthritis Drugs Market Size by Sales Channel & CAGR (2025-2032)

• Market Overview
• Prescription
• Over-the-Counter (OTC)

Global Rheumatoid Arthritis Drugs Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral

Global Rheumatoid Arthritis Drugs Market Size & CAGR (2025-2032)

• North America (Molecule, Sales Channel, Route of Administration)
  • US
  • Canada
• Europe (Molecule, Sales Channel, Route of Administration)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Molecule, Sales Channel, Route of Administration)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Molecule, Sales Channel, Route of Administration)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Molecule, Sales Channel, Route of Administration)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chugai Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Kirin Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations